Executive Committee

iA Financial Group announces changes to its Executive Committee

Retrieved on: 
Thursday, May 9, 2024

QUEBEC CITY, May 9, 2024 /CNW/ - iA Financial Group (TSX: IAG) announces today the following changes to its Executive Committee.

Key Points: 
  • QUEBEC CITY, May 9, 2024 /CNW/ - iA Financial Group (TSX: IAG) announces today the following changes to its Executive Committee.
  • After 25 years of dedicated services to iA Financial Group, Michael L. Stickney, Executive Vice-President, Chief Growth Officer US Operations, Co-Head of Acquisitions, has informed us of his intention to retire in the coming months.
  • Mr. O'Brien has joined iA in 2015 and brings close to 30 years experience in successfully leading and growing businesses in the financial sector.
  • Mr. Pouliot will join the iA Financial Group Executive Committee.

Lonza Announces Results of the 2024 Annual General Meeting – All Motions Proposed by Board of Directors Approved

Retrieved on: 
Friday, May 10, 2024

40.28% of the share capital was represented at the AGM, with attending and represented shareholders collectively holding a total of 29,994,055 shares.

Key Points: 
  • 40.28% of the share capital was represented at the AGM, with attending and represented shareholders collectively holding a total of 29,994,055 shares.
  • The Board members standing for re-election were all elected for a further term in office of one year.
  • Jean-Marc Huët was elected to the Board of Directors and to the role of Chairman of the Board of Directors for a term of one year.
  • A dividend of CHF 4.00 per share was proposed by the Board of Directors and approved by the shareholders.

Holcim Shareholders approve all proposals at 2024 Annual General Meeting

Retrieved on: 
Friday, May 10, 2024

Holcim’s 2024 Annual General Meeting took place at the Bossard Arena in Zug today.

Key Points: 
  • Holcim’s 2024 Annual General Meeting took place at the Bossard Arena in Zug today.
  • Shareholders confirmed the following members of the Nomination, Compensation & Governance Committee: Ilias Läber, Jürg Oleas, Claudia Sender Ramirez and Hanne Sørensen.
  • Shareholders approved the annual report and annual financial statements of the Group and of Holcim Ltd.
  • The full results of the Annual General Meeting and speeches from the Chairman, CEO and CFO are available here .

Brookfield Asset Management and Castlelake to Enter into Strategic Partnership

Retrieved on: 
Monday, May 6, 2024

BROOKFIELD NEWS, May 06, 2024 (GLOBE NEWSWIRE) -- Brookfield Asset Management (NYSE: BAM, TSX: BAM) (“Brookfield”) and Castlelake L.P. (“Castlelake”), an alternatives asset manager specializing in asset-based private credit including aviation and specialty finance, today announced that they have entered into an agreement whereby Brookfield will acquire a 51% stake in Castlelake’s fee-related earnings.

Key Points: 
  • BROOKFIELD NEWS, May 06, 2024 (GLOBE NEWSWIRE) -- Brookfield Asset Management (NYSE: BAM, TSX: BAM) (“Brookfield”) and Castlelake L.P. (“Castlelake”), an alternatives asset manager specializing in asset-based private credit including aviation and specialty finance, today announced that they have entered into an agreement whereby Brookfield will acquire a 51% stake in Castlelake’s fee-related earnings.
  • The amount of capital to be invested will be approximately $1.5 billion, including capital to be invested in Castlelake’s investment strategies by Brookfield Reinsurance.
  • The partnership will allow Castlelake and Brookfield to collaborate and expand Castlelake’s differentiated asset-based investment business.
  • Craig Noble, CEO of Brookfield Credit said, “We are thrilled to be partnering with Castlelake, a leading asset-based private credit business with an exceptional management team.

Alcon Announces Results of 2024 Annual General Meeting

Retrieved on: 
Wednesday, May 8, 2024

Alcon Inc. (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the approval of all proposed binding resolutions at its 2024 Annual General Meeting (AGM).

Key Points: 
  • Alcon Inc. (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the approval of all proposed binding resolutions at its 2024 Annual General Meeting (AGM).
  • In two separate binding votes, shareholders approved the maximum aggregate amount of compensation of the Board of Directors for the next term of office ending at the 2025 Annual General Meeting, and the Executive Committee for 2025 financial year.
  • Alcon shareholders approved the operating and financial review of Alcon Inc., the annual financial statements of Alcon Inc. and the consolidated financial statements for 2023.
  • Hartmann Dreyer Attorneys-at-Law was also re-elected as the independent representative for a term of one year extending until the 2025 AGM.

California Desalination Association Welcomes Lacy Carothers, California American Water Director of Engineering, to Executive Committee

Retrieved on: 
Tuesday, May 7, 2024

The California Desalination Association (CalDesal) today announced the unanimous appointment of Lacy Carothers, PE, Director of Engineering for California American Water, to its Executive Committee.

Key Points: 
  • The California Desalination Association (CalDesal) today announced the unanimous appointment of Lacy Carothers, PE, Director of Engineering for California American Water, to its Executive Committee.
  • View the full release here: https://www.businesswire.com/news/home/20240507867211/en/
    Lacy Carothers, PE, Director of Engineering for California American Water, has been appointed to the CalDesal Executive Committee.
  • “We’re all very excited to have Lacy join our Executive Committee,” said Glenn Farrel, Executive Director of CalDesal.
  • As a member of the CalDesal Executive Committee, Carothers will play a key role in shaping the association's advocacy efforts and advancing policies that promote desalination development throughout California.

Vivodyne Appoints Julie O'Shaughnessy as Chief Operating Officer

Retrieved on: 
Tuesday, May 7, 2024

Vivodyne , a pioneering biotech company that grows and tests on lab-grown human tissues to accelerate therapeutics discovery and development, today announced the appointment of Julie O'Shaughnessy as Chief Operating Officer.

Key Points: 
  • Vivodyne , a pioneering biotech company that grows and tests on lab-grown human tissues to accelerate therapeutics discovery and development, today announced the appointment of Julie O'Shaughnessy as Chief Operating Officer.
  • In her new role, Julie will oversee business operations, strategic planning, finance, people operations, and multisite expansion, driving the company's operational excellence and strategic growth initiatives.
  • View the full release here: https://www.businesswire.com/news/home/20240506648531/en/
    Prior to joining Vivodyne, Julie served in key leadership roles at Resilience and Amazon Web Services (AWS).
  • “Julie is leading essential functions at the intersection of people, finance, and business operations, and her exceptional leadership qualities have been constantly evident since joining.

Amyris Announces Kathy Fortmann as New CEO

Retrieved on: 
Tuesday, May 7, 2024

EMERYVILLE, Calif., May 7, 2024 /PRNewswire/ -- Amyris, Inc., a vertically integrated synthetic biology company that creates sustainable, market-ready ingredients utilizing proprietary advanced precision fermentation technology and world-class platforms, today announced that, following the effectiveness of its reorganization, Amyris has appointed Kathy L. Fortmann as Chief Executive Officer ("CEO") effective immediately.

Key Points: 
  • EMERYVILLE, Calif., May 7, 2024 /PRNewswire/ -- Amyris, Inc., a vertically integrated synthetic biology company that creates sustainable, market-ready ingredients utilizing proprietary advanced precision fermentation technology and world-class platforms, today announced that, following the effectiveness of its reorganization, Amyris has appointed Kathy L. Fortmann as Chief Executive Officer ("CEO") effective immediately.
  • Ms. Fortmann brings almost 35 years of global business experience across a range of industries including specialty chemicals and ingredients.
  • "I've long admired Amyris' leading science and technology capabilities and its impressive product portfolio and R&D pipeline," commented Ms. Fortmann.
  • Ms. Fortmann, along with Scott White, will join John Doerr and Ryan Panchadsaram as members of the Board of Directors of Amyris.

Amit Trehan Joins Cahill's New York Office as a Bankruptcy and Restructuring Partner

Retrieved on: 
Tuesday, May 7, 2024

NEW YORK, May 7, 2024 /PRNewswire/ -- Cahill Gordon & Reindel LLP announced today that Amit Trehan has joined the firm as a partner in New York, strengthening its Bankruptcy & Restructuring practice.

Key Points: 
  • NEW YORK, May 7, 2024 /PRNewswire/ -- Cahill Gordon & Reindel LLP announced today that Amit Trehan has joined the firm as a partner in New York, strengthening its Bankruptcy & Restructuring practice.
  • "Having spent the last dozen years in two different leading roles for one of the world's most impressive financial institutions, Amit brings to Cahill extensive experience managing distressed credits.
  • "The challenges he tackled there with such success will serve as a powerful foundation as he guides Cahill's clients through their bankruptcy and restructuring deals."
  • Mr. Trehan is the second lateral partner to enter Cahill's bankruptcy practice in thirteen months, following Joel Moss, who joined as a Co-Chair in March 2023.

Lucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of Directors

Retrieved on: 
Tuesday, May 7, 2024

NEW YORK, May 7, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the Company has closed a Series B-1 Preferred Stock offering led by one of the Company's long-time institutional investors, with gross proceeds of $11.6 million, bringing the total Series B / B-1 gross proceeds to $29.8 million. The offering provides the Company with significant working capital to execute its business plan as it approaches critical reimbursement milestones. The Company also announced that its Board of Directors has appointed healthcare industry veteran Dennis Matheis to serve as a Director, effective May 6, 2024.

Key Points: 
  • The Company also announced that its Board of Directors has appointed healthcare industry veteran Dennis Matheis to serve as a Director, effective May 6, 2024.
  • We are extremely fortunate that Dennis Matheis, a leading industry figure, has agreed to join the Lucid team."
  • Previously, in March 2024, the Company closed on $18.6 million in gross proceeds from a Series B Preferred Stock offering on comparable terms.
  • With this Series B-1 closing, Lucid has now completed its approximately $30 million, Board-approved Series B Preferred Stock offering.